Clinical trial
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
NCT00184743 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00184743 |
|---|---|
| Title | Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) |
| Official title | Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Disorder, Adult Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | somatropin |
| Enrollment | 112 |
| Start date | Dec 6, 2003 |
| Primary completion | Dec 28, 2005 |
| Completion | Dec 28, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Feb 28, 2017 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: